Suppr超能文献

多巴胺 D2L 受体和神经降压素 NTS1 受体之间的交叉受体相互作用调节多巴胺能药物的结合亲和力。

Cross-receptor interactions between dopamine D2L and neurotensin NTS1 receptors modulate binding affinities of dopaminergics.

机构信息

Department of Chemistry and Pharmacy, Emil Fischer Center, Friedrich-Alexander University , Schuhstrasse 19, D- 91052 Erlangen, Germany.

出版信息

ACS Chem Neurosci. 2011 Jun 15;2(6):308-16. doi: 10.1021/cn200020y. Epub 2011 Apr 11.

Abstract

Dopaminergic systems have been described to functionally interact with the neuromodulatory peptide neurotensin. Employing fluorescence detected coimmunoprecipitation and radioligand binding experiments, we herein demonstrate that coexpression of dopamine D(2L) receptor and the neurotensin receptor subtype NTS(1) leads to physical interaction and the formation of heteromers in transfected human embryonic kidney 293 cells. In this in vitro system, a trans-inhibitory effect on the agonist binding affinity of D(2) was observed in presence of neurotensin. To correlate between the functional properties of dopaminergic agents and the magnitude of neurotensin-induced modulation of D(2L) binding affinities in cells coexpressing D(2L) and NTS(1), a structurally diverse set of dopamine receptor agonists, partial agonists, and antagonists was tested. Ligand specific profiles indicating substantial bias between ligand efficacy and transmodulation were discovered, suggesting a heteromerization-based functional selectivity. In the presence of neurotensin, the novel D(2) agonist FAUC 326 displayed a 34-fold decrease of binding affinity in cells coexpressing D(2L) and NTS(1).

摘要

多巴胺能系统被描述为与神经调节肽神经降压素在功能上相互作用。通过荧光检测共免疫沉淀和放射性配体结合实验,我们在此证明多巴胺 D2L 受体和神经降压素受体亚型 NTS1 的共表达导致在转染的人胚肾 293 细胞中物理相互作用和异源三聚体的形成。在这个体外系统中,在神经降压素存在的情况下观察到对激动剂结合亲和力的反式抑制作用。为了将多巴胺能药物的功能特性与在共表达 D2L 和 NTS1 的细胞中神经降压素诱导的 D2L 结合亲和力调制的程度相关联,测试了一组结构多样的多巴胺受体激动剂、部分激动剂和拮抗剂。发现配体特异性谱表明配体效能和反式调制之间存在显著的偏向,这表明存在基于异源三聚体的功能选择性。在神经降压素存在的情况下,新型 D2 激动剂 FAUC 326 在共表达 D2L 和 NTS1 的细胞中的结合亲和力下降了 34 倍。

相似文献

引用本文的文献

1
CORUM in 2024: protein complexes as drug targets.2024年的CORUM:作为药物靶点的蛋白质复合物
Nucleic Acids Res. 2025 Jan 6;53(D1):D651-D657. doi: 10.1093/nar/gkae1033.
7
Structure-Guided Design of G-Protein-Coupled Receptor Polypharmacology.基于结构的 G 蛋白偶联受体多靶性药物设计。
Angew Chem Int Ed Engl. 2021 Aug 9;60(33):18022-18030. doi: 10.1002/anie.202101478. Epub 2021 Jul 16.

本文引用的文献

6
Class A GPCR heterodimers: evidence from binding studies.A 类 G 蛋白偶联受体二聚体:来自结合研究的证据。
Trends Pharmacol Sci. 2010 Nov;31(11):499-508. doi: 10.1016/j.tips.2010.08.003. Epub 2010 Oct 1.
7
Receptor heteromerization and drug discovery.受体异源二聚化与药物发现。
Trends Pharmacol Sci. 2010 Mar;31(3):124-30. doi: 10.1016/j.tips.2009.11.008. Epub 2010 Jan 7.
10
How reliable are G-protein-coupled receptor antibodies?G蛋白偶联受体抗体的可靠性如何?
Naunyn Schmiedebergs Arch Pharmacol. 2009 Apr;379(4):385-8. doi: 10.1007/s00210-009-0395-y. Epub 2009 Jan 27.

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验